It was verified that Resibufogenin could inhibit renal cell carcinoma in multiple targets, multiple functions, and multiple pathways, and could change the morphology of Caki-1 cells, inhibit cell proliferation, inhibit cell migration, induce apoptosis and necrosis, and regulate the expression of MAPK1 and PRKCB in Caki-1 cells. The gene discussed is MAPK1; the disease is renal cell carcinoma.